Jamal BaigAssociate Director of Pharmacovigilance
Merck Sharp And Dohme (MSD)
Data-mining during all stages of drug development: from drug discovery to best practices in post-marketing surveillance
Converting ICSRs into structured formats and evaluating if a signal should be investigated
Examining aggregate reports periodically to identify signals not detected from individual data
Revising your safety monitoring practices to changing regulatory standards
Compare and contrast existing PV databases: how can you ensure quality?